文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

血清胰岛素样生长因子结合蛋白 2 水平作为与胰腺导管腺癌相关的营养不良和肌肉减少症的生物标志物。

Serum insulin-like growth factor binding protein 2 levels as biomarker for pancreatic ductal adenocarcinoma-associated malnutrition and muscle wasting.

机构信息

Department of Nutrition Therapy, Tianjin Medical University Cancer Institute and Hospital/National Clinical Research Center for Cancer/Key Laboratory of Cancer Prevention and Therapy, Tianjin/Tianjin's Clinical Research Center for Cancer, Tianjin, China.

Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Huanhu West Road, Hexi District, Tianjin, 300060, China.

出版信息

J Cachexia Sarcopenia Muscle. 2021 Jun;12(3):704-716. doi: 10.1002/jcsm.12692. Epub 2021 Mar 24.


DOI:10.1002/jcsm.12692
PMID:33763996
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8200427/
Abstract

BACKGROUND: Malnutrition and muscle wasting are common features frequently observed in pancreatic ductal adenocarcinoma (PDAC) patients with cancer cachexia. They are associated with reduced survival and quality of life. Nutrition therapy is an important part of multimodal cancer care in PDAC. However, due to the complexity of nutrition assessment, only 30-60% of patients with nutritional risks receive nutritional treatment at present. It is important to identify biomarkers that may be used to improve management of PDAC-associated malnutrition. Serum insulin-like growth factor binding protein 2 (IGFBP2) has emerged as a potential serum biomarker in a variety of tumours. However, its association with malnutrition and muscle wasting in PDAC is unclear. METHODS: We evaluated the tumour IGFBP2 expression and serum IGFBP2 level in 98 PDAC patients using immunohistochemistry and enzyme-linked immunosorbent assay and analysed the correlation between them. Furthermore, we explored the relationship between IGFBP2 of both tumour and serum and nutritional status (Patient-Generated Subjective Global Assessment and skeletal muscle index). Pan02 IGFBP2 stable transfection cell lines, Pan02 PLV-IGFBP2 cells, and PLKO-IGFBP2 cells were injected subcutaneously into the flank of C57BL/6 mouse. Serum IGFBP2 levels, food intake, and body weight of these mice were measured. The degree of muscle atrophy is characterized by haematoxylin and eosin, Oil Red O, and Masson's trichrome staining. The mRNA and protein expression of several essential muscle-related signal proteins such as atrogin-1 and muscle RING finger 1 was measured. RESULTS: Among 98 patients, we found that tumour IGFBP2 expression is related to plasma IGFBP2 levels (r  = 0.562, P < 0.001), and they significantly increased among patients with Patient-Generated Subjective Global Assessment ≥9 and correlated with overall survival. Moreover, serum IGFBP2 level is negatively correlated with skeletal muscle index (r  = -0.600, P < 0.001) and Hounsfield units (r  = -0.532, P < 0.001). In mice injected with Pan02 PLV-IGFBP2 cell, circulating IGFBP2 was elevated while body weight and food intake were decreased when compared with Pan02 PLV-Control group. These mice also exhibited significantly aggravated muscle fibre atrophy, lipid deposition, and increased collagen tissue, and the expression of mRNA and protein of atrogin-1 and muscle RING finger 1 in the gastrocnemius muscle is increased. Conversely, these symptoms were alleviated in the PLKO-IGFBP2 group. CONCLUSIONS: In the current study, there is a significant correlation between serum IGFBP2 levels, malnutrition, and muscle atrophy in PDAC. Our results suggested that serum IGFBP2 level might be a promising biomarker and intervention targets for PDAC-associated severe malnutrition and muscle wasting.

摘要

背景:营养不良和肌肉减少症是胰腺癌(PDAC)患者恶病质中常见的特征。它们与降低的生存和生活质量相关。营养治疗是 PDAC 多模式癌症治疗的重要组成部分。然而,由于营养评估的复杂性,目前只有 30-60%有营养风险的患者接受营养治疗。确定可能用于改善 PDAC 相关营养不良管理的生物标志物非常重要。血清胰岛素样生长因子结合蛋白 2(IGFBP2)已成为多种肿瘤中潜在的血清生物标志物。然而,其与 PDAC 中营养不良和肌肉减少的关系尚不清楚。 方法:我们使用免疫组织化学和酶联免疫吸附试验评估了 98 名 PDAC 患者的肿瘤 IGFBP2 表达和血清 IGFBP2 水平,并分析了它们之间的相关性。此外,我们还探讨了肿瘤和血清 IGFBP2 与营养状况(患者生成的主观整体评估和骨骼肌指数)之间的关系。将 Pan02 IGFBP2 稳定转染细胞系 Pan02 PLV-IGFBP2 细胞和 PLKO-IGFBP2 细胞皮下注射到 C57BL/6 小鼠的侧腹。测量这些小鼠的血清 IGFBP2 水平、食物摄入量和体重。通过苏木精和伊红、油红 O 和 Masson 三色染色来表征肌肉萎缩的程度。测量几种必需的肌肉相关信号蛋白(如 atrogin-1 和肌肉 RING 指蛋白 1)的 mRNA 和蛋白表达。 结果:在 98 名患者中,我们发现肿瘤 IGFBP2 表达与血浆 IGFBP2 水平相关(r=0.562,P<0.001),并且在患者生成的主观整体评估≥9 分的患者中显著增加,并与总生存相关。此外,血清 IGFBP2 水平与骨骼肌指数(r=-0.600,P<0.001)和 Hounsfield 单位(r=-0.532,P<0.001)呈负相关。在注射 Pan02 PLV-IGFBP2 细胞的小鼠中,与 Pan02 PLV-Control 组相比,循环 IGFBP2 升高,体重和食物摄入量降低。这些小鼠还表现出明显加重的肌肉纤维萎缩、脂质沉积和增加的胶原组织,以及腓肠肌中 atrogin-1 和肌肉 RING 指蛋白 1 的 mRNA 和蛋白表达增加。相反,在 PLKO-IGFBP2 组中这些症状得到缓解。 结论:在目前的研究中,PDAC 患者的血清 IGFBP2 水平、营养不良和肌肉萎缩之间存在显著相关性。我们的结果表明,血清 IGFBP2 水平可能是 PDAC 相关严重营养不良和肌肉减少症的有前途的生物标志物和干预靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5248/8200427/94fa19beef53/JCSM-12-704-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5248/8200427/9c73f5feb690/JCSM-12-704-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5248/8200427/6249665b5097/JCSM-12-704-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5248/8200427/8e58b518a23b/JCSM-12-704-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5248/8200427/1e1c7086fd14/JCSM-12-704-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5248/8200427/2c6e17b09b56/JCSM-12-704-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5248/8200427/94fa19beef53/JCSM-12-704-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5248/8200427/9c73f5feb690/JCSM-12-704-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5248/8200427/6249665b5097/JCSM-12-704-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5248/8200427/8e58b518a23b/JCSM-12-704-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5248/8200427/1e1c7086fd14/JCSM-12-704-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5248/8200427/2c6e17b09b56/JCSM-12-704-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5248/8200427/94fa19beef53/JCSM-12-704-g006.jpg

相似文献

[1]
Serum insulin-like growth factor binding protein 2 levels as biomarker for pancreatic ductal adenocarcinoma-associated malnutrition and muscle wasting.

J Cachexia Sarcopenia Muscle. 2021-6

[2]
The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy.

J Cachexia Sarcopenia Muscle. 2019-7-8

[3]
Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin.

J Cachexia Sarcopenia Muscle. 2022-8

[4]
Increased myocellular lipid and IGFBP-3 expression in a pre-clinical model of pancreatic cancer-related skeletal muscle wasting.

J Cachexia Sarcopenia Muscle. 2021-6

[5]
Hepatic signal transducer and activator of transcription-3 signalling drives early-stage pancreatic cancer cachexia via suppressed ketogenesis.

J Cachexia Sarcopenia Muscle. 2024-6

[6]
Serum IGFBP2 Level Is a New Candidate Biomarker of Severe Malnutrition in Advanced Lung Cancer.

Nutr Cancer. 2020

[7]
MEF2c-Dependent Downregulation of Myocilin Mediates Cancer-Induced Muscle Wasting and Associates with Cachexia in Patients with Cancer.

Cancer Res. 2020-3-4

[8]
Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer.

HPB (Oxford). 2014-7

[9]
IGFBP2 promotes tumor progression by inducing alternative polarization of macrophages in pancreatic ductal adenocarcinoma through the STAT3 pathway.

Cancer Lett. 2021-3-1

[10]
Phases of Metabolic and Soft Tissue Changes in Months Preceding a Diagnosis of Pancreatic Ductal Adenocarcinoma.

Gastroenterology. 2019-1-22

引用本文的文献

[1]
Role of m6A RNA methylation regulators in pancreatic cancer: interactions and potential implications.

Cancer Cell Int. 2025-8-4

[2]
Intratumor HIF-1α modulates production of a cachectic ligand to cause host wasting.

Cell Insight. 2025-4-8

[3]
Race-based differences in serum biomarkers for cancer-associated cachexia in a diverse cohort of patients with pancreatic ductal adenocarcinoma.

Res Sq. 2025-2-10

[4]
A tumor-secreted protein utilizes glucagon release to cause host wasting.

Cell Discov. 2025-2-10

[5]
Plasma biomarkers in patients with age-related sarcopenia: a proteomic exploration and experimental validation.

Aging Clin Exp Res. 2024-12-27

[6]
Combination of Waist Circumference and Circulating Levels of IGFBP-2 as a Simple Screening Tool for Early Detection of Metabolic Dysfunction-Associated Steatotic Liver Disease.

Diabetes Metab Syndr Obes. 2024-9-5

[7]
A novel antidiuretic hormone governs tumour-induced renal dysfunction.

Nature. 2023-12

[8]
Convergent insulin and TGF-β signalling drives cancer cachexia by promoting aberrant fat body ECM accumulation in a Drosophila tumour model.

EMBO Rep. 2023-12-6

[9]
Proteomic Serum Profiling of Holstein Friesian Cows with Different Pathological Forms of Bovine Paratuberculosis Reveals Changes in the Acute-Phase Response and Lipid Metabolism.

J Proteome Res. 2024-8-2

[10]
The roles of the native cell differentiation program aberrantly recapitulated in Drosophila intestinal tumors.

Cell Rep. 2023-10-31

本文引用的文献

[1]
Pancreatic Cancer and Cachexia-Metabolic Mechanisms and Novel Insights.

Nutrients. 2020-5-26

[2]
Serum IGFBP2 Level Is a New Candidate Biomarker of Severe Malnutrition in Advanced Lung Cancer.

Nutr Cancer. 2020

[3]
Understanding cachexia in the context of metastatic progression.

Nat Rev Cancer. 2020-3-31

[4]
Cancer cachexia and its pathophysiology: links with sarcopenia, anorexia and asthenia.

J Cachexia Sarcopenia Muscle. 2020-6

[5]
IGFBP2: integrative hub of developmental and oncogenic signaling network.

Oncogene. 2020-3

[6]
The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview.

Cancer Biol Med. 2019-11

[7]
Sarcopenia as a predictor of poor surgical and oncologic outcomes after abdominal surgery for digestive tract cancer: A prospective cohort study.

Clin Nutr. 2018-12-29

[8]
Molecular therapeutic strategies targeting pancreatic cancer induced cachexia.

World J Gastrointest Surg. 2018-12-27

[9]
Cancer Cachexia: More Than Skeletal Muscle Wasting.

Trends Cancer. 2018-12

[10]
Clinical Value of Nutritional Status in Cancer: What is its Impact and how it Affects Disease Progression and Prognosis?

Nutr Cancer. 2017

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索